Home › Companies › SYROS PHARMACEUTICALS INC. › 2023-2024
At SYROS PHARMACEUTICALS INC.'s shareholder meeting held June 5, 2024, in the 2023-2024 proxy season, 67 asset managers reported how they voted on 8 ballot items in their SEC Form N-PX filings, covering 235 separate fund positions. On the most widely held item on that ballot — APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE… — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: SYROS PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 6, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and SYROS PHARMACEUTICALS INC.’s Form 8-K, filed June 6, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 5, 2024: 8 items on SYROS PHARMACEUTICALS INC.’s Form 8-K, filed June 6, 2024: 8 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024
Explore SYROS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are SYROS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 6, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Srinivas Akkaraju, M.D., Ph.D. | 9,937,523 | -- | -- | 7,569,838 | 4,293,683 | 57% | Not verified | — |
| Elect Director: Deborah Dunsire, M.D. | 17,450,919 | -- | -- | 56,442 | 4,293,683 | 99.6% | Not verified | — |
| Elect Director: Richard A. Young, Ph.D. | 10,222,669 | -- | -- | 7,284,692 | 4,293,683 | 58% | Not verified | — |
| 2. The approval of an amendment to the 2022 EIP to increase the number of shares of the Company's common stock available for issuance thereunder by 1,750,000 shares | 17,270,024 | 227,218 | 10,119 | -- | 4,293,683 | 99% | Not verified | — |
| 3. The approval of an amendment to the Syros Pharmaceuticals, Inc. Restated Certificate of Incorporation, as amended, to (i) increase the number of authorized shares of the Company's capital stock from 80,000,000 shares to 150,000,000 shares, and (ii) increase | 17,221,927 | 226,689 | 58,745 | -- | 4,293,683 | 99% | Not verified | — |
| 4. The approval of an amendment to the Syros Pharmaceuticals, Inc. Restated Certificate of Incorporation, as amended, to reflect new Delaware law provisions regarding officer exculpation (the " Officer Exculpation Amendment ") | 15,600,986 | 1,892,849 | 13,526 | -- | 4,293,683 | 89% | Not verified | — |
| 5. The ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 | 21,649,497 | 85,571 | 65,976 | -- | -- | 99.6% | Not verified | — |
| 6. The approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers | 17,127,081 | 359,883 | 20,397 | -- | 4,293,683 | 98% | Not verified | — |
Source: SYROS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 6, 2024 — read the filing on EDGAR.
Each item below shows how the 67 asset managers that disclosed a SYROS PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
Description as filed by funds: Election of Class II directors, each to serve for a three-year term expiring at the Company's 2027 annual meeting of stockholders and until their successor has been duly elected and qualified: Deborah Dunsire, M.D.
SYROS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Deborah Dunsire, M.D.”): 17,450,919 for, 56,442 withheld, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.6% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 13 asset managers below reported 1,111,331 for, 6,575 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 913,296 | 0 | 0 | 0 | For |
| Fidelity | 95,254 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 50,670 | 0 | 0 | 0 | For |
| BlackRock | 22,727 | 0 | 0 | 0 | For |
| T. Rowe Price | 18,727 | 0 | 0 | 0 | For |
| Charles Schwab | 4,670 | 0 | 0 | 0 | For |
| Equitable | 4,017 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 3,453 | Withhold |
| Jackson National | 0 | 0 | 0 | 3,122 | Withhold |
| American Century | 1,593 | 0 | 0 | 0 | For |
| John Hancock | 312 | 0 | 0 | 0 | For |
| Guggenheim | 34 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 31 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
58% Majority: yes · of votes cast
Description as filed by funds: Election of Class II directors, each to serve for a three-year term expiring at the Company's 2027 annual meeting of stockholders and until their successor has been duly elected and qualified: Richard A. Young, Ph.D.
SYROS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Richard A. Young, Ph.D.”): 10,222,669 for, 7,284,692 withheld, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 58% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 13 asset managers below reported 1,027,277 for, 90,629 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 913,296 | 0 | 0 | 0 | For |
| Fidelity | 95,254 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 50,670 | Withhold |
| BlackRock | 0 | 0 | 0 | 22,727 | Withhold |
| T. Rowe Price | 18,727 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 4,670 | Withhold |
| Equitable | 0 | 0 | 0 | 4,017 | Withhold |
| Dimensional | 0 | 0 | 0 | 3,453 | Withhold |
| Jackson National | 0 | 0 | 0 | 3,122 | Withhold |
| American Century | 0 | 0 | 0 | 1,593 | Withhold |
| John Hancock | 0 | 0 | 0 | 312 | Withhold |
| Guggenheim | 0 | 0 | 0 | 34 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 0 | 0 | 0 | 31 | Withhold |
Combines 3 wordings of this item as funds reported it.
57% Majority: yes · of votes cast
Description as filed by funds: Election of Class II directors, each to serve for a three-year term expiring at the Company's 2027 annual meeting of stockholders and until their successor has been duly elected and qualified: Srinivas Akkaraju, M.D., Ph.D.
SYROS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Srinivas Akkaraju, M.D., Ph.D.”): 9,937,523 for, 7,569,838 withheld, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 57% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 13 asset managers below reported 1,117,906 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 0 | 0 | 913,296 | Withhold |
| Fidelity | 0 | 0 | 0 | 95,254 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 50,670 | Withhold |
| BlackRock | 0 | 0 | 0 | 22,727 | Withhold |
| T. Rowe Price | 0 | 0 | 0 | 18,727 | Withhold |
| Charles Schwab | 0 | 0 | 0 | 4,670 | Withhold |
| Equitable | 0 | 0 | 0 | 4,017 | Withhold |
| Dimensional | 0 | 0 | 0 | 3,453 | Withhold |
| Jackson National | 0 | 0 | 0 | 3,122 | Withhold |
| American Century | 0 | 0 | 0 | 1,593 | Withhold |
| John Hancock | 0 | 0 | 0 | 312 | Withhold |
| Guggenheim | 0 | 0 | 0 | 34 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 0 | 0 | 0 | 31 | Withhold |
Combines 3 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Description as filed by funds: Approval of an amendment to the Syros Pharmaceuticals, Inc. Restated Certificate of incorporation, as amended, to reflect new Delaware law provisions regarding officer exculpation;
SYROS PHARMACEUTICALS INC.’s own tally for this item (“4. The approval of an amendment to the Syros Pharmaceuticals, Inc. Restated Certificate of Incorporation, as amended, to reflect new Delaware law provisions regarding officer exculpation (the " Officer Exculpation Amendm”): 15,600,986 for, 1,892,849 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 13 asset managers below reported 1,117,906 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 913,296 | 0 | 0 | 0 | For |
| Fidelity | 95,254 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 50,670 | 0 | 0 | 0 | For |
| BlackRock | 22,727 | 0 | 0 | 0 | For |
| T. Rowe Price | 18,727 | 0 | 0 | 0 | For |
| Charles Schwab | 4,670 | 0 | 0 | 0 | For |
| Equitable | 4,017 | 0 | 0 | 0 | For |
| Dimensional | 3,453 | 0 | 0 | 0 | For |
| Jackson National | 3,122 | 0 | 0 | 0 | For |
| American Century | 1,593 | 0 | 0 | 0 | For |
| John Hancock | 312 | 0 | 0 | 0 | For |
| Guggenheim | 34 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 31 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: Approval of an amendment to the Syros Pharmaceuticals, Inc. Restated Certificate of Incorporation, as amended, to (i) increase the number of authorized shares of our capital stock from 80,000,000 shares to 150,000,000 shares, and (ii) increase the number of authorized shares of our common stock from 70,000,000 shares to 140,000,000 shares;
SYROS PHARMACEUTICALS INC.’s own tally for this item (“3. The approval of an amendment to the Syros Pharmaceuticals, Inc. Restated Certificate of Incorporation, as amended, to (i) increase the number of authorized shares of the Company's capital stock from 80,000,000 shares ”): 17,221,927 for, 226,689 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 13 asset managers below reported 1,117,906 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 913,296 | 0 | 0 | 0 | For |
| Fidelity | 95,254 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 50,670 | 0 | 0 | 0 | For |
| BlackRock | 22,727 | 0 | 0 | 0 | For |
| T. Rowe Price | 18,727 | 0 | 0 | 0 | For |
| Charles Schwab | 4,670 | 0 | 0 | 0 | For |
| Equitable | 4,017 | 0 | 0 | 0 | For |
| Dimensional | 3,453 | 0 | 0 | 0 | For |
| Jackson National | 3,122 | 0 | 0 | 0 | For |
| American Century | 1,593 | 0 | 0 | 0 | For |
| John Hancock | 312 | 0 | 0 | 0 | For |
| Guggenheim | 34 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 31 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: Approval of an amendment to the Syros Pharmaceuticals, Inc. 2022 Equity Incentive Plan to increase the number of shares of our common stock available for issuance thereunder by 1,750,000 shares;
SYROS PHARMACEUTICALS INC.’s own tally for this item (“2. The approval of an amendment to the 2022 EIP to increase the number of shares of the Company's common stock available for issuance thereunder by 1,750,000 shares”): 17,270,024 for, 227,218 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 13 asset managers below reported 1,116,313 for, 1,593 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 913,296 | 0 | 0 | 0 | For |
| Fidelity | 95,254 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 50,670 | 0 | 0 | 0 | For |
| BlackRock | 22,727 | 0 | 0 | 0 | For |
| T. Rowe Price | 18,727 | 0 | 0 | 0 | For |
| Charles Schwab | 4,670 | 0 | 0 | 0 | For |
| Equitable | 4,017 | 0 | 0 | 0 | For |
| Dimensional | 3,453 | 0 | 0 | 0 | For |
| Jackson National | 3,122 | 0 | 0 | 0 | For |
| American Century | 0 | 1,593 | 0 | 0 | Against |
| John Hancock | 312 | 0 | 0 | 0 | For |
| Guggenheim | 34 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 31 | 0 | 0 | 0 | For |
Combines 10 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.
SYROS PHARMACEUTICALS INC.’s own tally for this item (“6. The approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers”): 17,127,081 for, 359,883 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 913,296 | 0 | 0 | 0 | For |
| Fidelity | 95,254 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 50,670 | 0 | 0 | Against |
| BlackRock | 22,727 | 0 | 0 | 0 | For |
| T. Rowe Price | 18,727 | 0 | 0 | 0 | For |
| Charles Schwab | 4,670 | 0 | 0 | 0 | For |
| Equitable | 4,017 | 0 | 0 | 0 | For |
| Dimensional | 3,453 | 0 | 0 | 0 | For |
| Jackson National | 3,122 | 0 | 0 | 0 | For |
| American Century | 0 | 1,593 | 0 | 0 | Against |
| John Hancock | 312 | 0 | 0 | 0 | For |
| Guggenheim | 34 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 31 | 0 | 0 | 0 | For |
Fund voting reports, all 13 managers: 1,065,643 for, 52,263 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,071,914 | 0 | 0 | 0 | For |
| Samsara BioCapital, LLC | 1,786,427 | 0 | 0 | 0 | For |
| Avidity Partners Management LP | 1,673,538 | 0 | 0 | 0 | For |
| Flagship Pioneering Inc. | 1,293,849 | 0 | 0 | 0 | For |
| Bain Capital Life Sciences Investors, LLC | 1,230,857 | 0 | 0 | 0 | For |
| Point72 | 1,122,291 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 828,485 | 0 | 0 | 0 | For |
| Opaleye Management Inc. | 827,634 | 0 | 0 | 0 | For |
| KENNEDY CAPITAL MANAGEMENT LLC | 235,273 | 137,996 | 0 | 0 | Mixed |
| Omega Fund Management, LLC | 0 | 0 | 251,270 | 0 | Abstain |
| UBS | 213,330 | 0 | 0 | 0 | For |
| BlackRock | 198,988 | 0 | 0 | 0 | For |
| Knott David M Jr | 167,948 | 0 | 0 | 0 | For |
| DAFNA Capital Management LLC | 135,850 | 0 | 0 | 0 | For |
| Exome Asset Management LLC | 118,878 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 114,479 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 108,175 | 0 | 0 | 0 | For |
| Renaissance | 105,574 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 92,734 | 0 | 0 | 0 | For |
| Two Sigma | 64,202 | 0 | 0 | 0 | For |
| State Street | 58,430 | 0 | 0 | 0 | For |
| LGT CAPITAL PARTNERS LTD. | 55,000 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0 | 51,500 | 0 | 0 | Against |
| 1492 Capital Management LLC | 39,244 | 0 | 0 | 0 | For |
| Northern Trust | 30,572 | 0 | 0 | 0 | For |
Institutional-manager reports, all 61 managers: 12,720,644 for, 191,089 against, 251,270 abstained. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
Description as filed by funds: Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
SYROS PHARMACEUTICALS INC.’s own tally for this item (“5. The ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 21,649,497 for, 85,571 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 13 asset managers below reported 1,117,906 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 913,296 | 0 | 0 | 0 | For |
| Fidelity | 95,254 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 50,670 | 0 | 0 | 0 | For |
| BlackRock | 22,727 | 0 | 0 | 0 | For |
| T. Rowe Price | 18,727 | 0 | 0 | 0 | For |
| Charles Schwab | 4,670 | 0 | 0 | 0 | For |
| Equitable | 4,017 | 0 | 0 | 0 | For |
| Dimensional | 3,453 | 0 | 0 | 0 | For |
| Jackson National | 3,122 | 0 | 0 | 0 | For |
| American Century | 1,593 | 0 | 0 | 0 | For |
| John Hancock | 312 | 0 | 0 | 0 | For |
| Guggenheim | 34 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 31 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 26,728,337 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 3.42% |
| 2 | Fidelity | 0.36% |
| 3 | BRIDGEWAY FUNDS INC | 0.19% |
| 4 | BlackRock | 0.09% |
| 5 | T. Rowe Price | 0.07% |
| 6 | Charles Schwab | 0.02% |
| 7 | Equitable | 0.02% |
| 8 | Dimensional | 0.01% |
| 9 | Jackson National | 0.01% |
| 10 | American Century | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 7.75% |
| 2 | Samsara BioCapital, LLC | 6.68% |
| 3 | Avidity Partners Management LP | 6.26% |
| 4 | Flagship Pioneering Inc. | 4.84% |
| 5 | Bain Capital Life Sciences Investors, LLC | 4.61% |
| 6 | Point72 | 4.20% |
| 7 | Deep Track Capital, LP | 3.10% |
| 8 | Opaleye Management Inc. | 3.10% |
| 9 | KENNEDY CAPITAL MANAGEMENT LLC | 1.40% |
| 10 | Omega Fund Management, LLC | 0.94% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Deep Track Biotechnology Master Fund, Ltd. | 11.10% | DEF14A |
| S | 10.69% | 13G |
| Entities affiliated with Invus Public Equities, L.P. | 9.37% | DEF14A |
| Avidity Partners Management LP | 7.66% | 13G |
| Adage Capital Partners LP | 7.55% | DEF14A |
| Srinivas Akkaraju, M.D., Ph.D. | 6.69% | DEF14A |
| Entities affiliated with Avidity Capital Partners | 6.26% | DEF14A |
| Entities affiliated with Blue Owl Capital Holdings LP | 5.59% | DEF14A |
| Entities affiliated with Point72 Asset Management, L.P. | 5.51% | DEF14A |
| Point72 | 5.51% | 13F |
Percentages above are of 26,728,337 shares outstanding, as reported by SYROS PHARMACEUTICALS INC. on its Form 10-Q dated May 7, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SYROS PHARMACEUTICALS INC.’s 10-Q dated May 7, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
SYROS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page).
proxyvotesnow.com, “SYROS PHARMACEUTICALS INC. 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/syros-pharmaceuticals-inc/2024 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.